Global Research Antibodies Market Expected to Grow with a CAGR of 6.2% During the Forecast Period, 2020-2027 – ResearchAndMarkets.com – Yahoo Finance

The "Research Antibodies Market Size, Share & Trends Analysis Report by Type (Monoclonal, Polyclonal), by End Use, by Product, by Technology, by Source, by Application (Oncology, Stem Cells), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period according to this report.

Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Further key findings from the report suggest:

Key Topics Covered:

Chapter 1 Methodology and Scope

1.1 Market segmentation & scope

1.2 Market definition

1.3 Information procurement

1.4 Information analysis

1.5 Market formulation & data visualization

1.6 Data validation & publishing

Chapter 2 Executive Summary

2.1 Market Outlook

2.2 Segment Outlook

2.3 Competitive Insights

Chapter 3 Research Antibodies Market Variables, Trends & Scope

3.1 Market Lineage Outlook

3.2 Penetration And Growth Prospect Mapping

3.3 Regulatory Framework

3.4 Market Dynamics

3.5 Research Antibodies Market Analysis Tools

Chapter 4 Research Antibodies Market - Competitive Analysis

4.1 Recent Developments & Impact Analysis, By Key Market Participants

4.2 Company Categorization

4.3 Public Companies

4.4 Private Companies

Chapter 5 Research Antibodies Market: Product Estimates And Trend Analysis

5.1 Definition & Scope

5.2 Product Market Share Analysis, 2019 & 2027

5.3 Segment Dashboard

5.4 Global Research Antibodies Market, By Product, 2016 To 2027

Story continues

5.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

5.6 Primary Antibodies

5.7 Secondary Antibodies

Chapter 6 Research Antibodies Market: Type Estimates And Trend Analysis

6.1 Definition & Scope

6.2 Type Market Share Analysis, 2019 & 2027

6.3 Segment Dashboard

6.4 Global Research Antibodies Market, By Type, 2016 To 2027

6.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

6.6 Monoclonal Antibodies

6.7 Polyclonal Antibodies

Chapter 7 Research Antibodies Market: Technology Estimates And Trend Analysis

7.1 Definition & Scope

7.2 Technology Market Share Analysis, 2019 & 2027

7.3 Segment Dashboard

7.4 Global Research Antibodies Market, By Technology, 2016 To 2027

7.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

7.6 Immunochemistry

7.7 Immunofluorescence

7.8 Western Blotting

7.9 Flow Cytometry

7.10 Immunoprecipitation

7.11 Elisa

7.12 Other Technologies

Chapter 8 Research Antibodies Market: Application Estimates And Trend Analysis

8.1 Definition & Scope

8.2 Application Market Share Analysis, 2019 & 2027

8.3 Segment Dashboard

8.4 Global Research Antibodies Market, By Application, 2016 To 2027

8.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

8.6 Infectious Diseases

8.7 Immunology

8.8 Oncology

8.9 Stem Cells

8.10 Neurobiology

8.11 Other Applications

Chapter 9 Research Antibodies Market: Source Estimates And Trend Analysis

9.1 Definition & Scope

9.2 Source Market Share Analysis, 2019 & 2027

9.3 Segment Dashboard

9.4 Global Research Antibodies Market, By Source, 2016 To 2027

9.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

9.6 Mouse Antibodies

9.7 Rabbit Antibodies

9.8 Goat Antibodies

9.9 Other Sources

Chapter 10 Research Antibodies Market: End Use Estimates And Trend Analysis

10.1 Definition & Scope

10.2 End Use Market Share Analysis, 2019 & 2027

10.3 Segment Dashboard

10.4 Global Research Antibodies Market, By End Use, 2016 To 2027

10.5 Market Size & Forecasts And Trend Analyses, 2016 To 2027

10.6 Academic & Research Institutes

10.7 Contract Research Organizations

10.8 Pharmaceutical & Biotechnology Companies

Chapter 11 Research Antibodies Market: Regional Estimates & Trend Analysis

11.1 Regional Market Snapshot

11.2 Market Share Analysis By Country, 2019

11.3 SWOT Analysis, By Factor

11.4 Market Size & Forecasts, And Trend Analysis, 2019 To 2026

11.4.1 North America

11.4.2 Europe

11.4.3 Asia Pacific

Original post:
Global Research Antibodies Market Expected to Grow with a CAGR of 6.2% During the Forecast Period, 2020-2027 - ResearchAndMarkets.com - Yahoo Finance

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting – BioSpace

SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma Inc., (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 29, 2020 at the San Diego Convention Center.

Details of the presentation are as follows:Title:Domain-specific antibodies to Neuropilin-2 implicate VEGF-C and not Semaphorin 3F in breast cancer stem cell functionSession Date and Time:Monday, Apr 27, 2020 9:00 AM - 12:30 PMAbstract Control Number:7308Session Category:Experimental and Molecular TherapeuticsSession Title:Identification of Molecular Targets 1Location: San Diego Convention Center, Exhibit Halls A-F, Poster Section 25Poster Board Number:14Permanent Abstract Number: 1785

About ATYR1923

aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, include statements regarding the potential therapeutic benefits and applications of our product candidates; our ability to successfully advance our product candidates, undertake certain development activities (such as the initiation of clinical trials, clinical trial enrollment, the conduct of clinical trials and the announcement of top-line results) and accomplish certain development goals, and the timing of such events; and the scope and strength of our intellectual property portfolio. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility of unexpected expenses or other demands on our cash resources, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

More here:
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting - BioSpace

The Global Cell Viability Assays MARKET is expected to grow by USD 1.40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -…

Global Cell Viability Assays Market 2020-2024 The analyst has been monitoring the global cell viability assays market and it is poised to grow by USD 1. 40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period.

New York, March 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Viability Assays Market 2020-2024" - https://www.reportlinker.com/p05868124/?utm_source=GNW Our reports on global cell viability assays market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by growing emphasis on timely diagnosis of diseases.In addition, growing focus on stem cell research is anticipated to boost the growth of the global cell viability assays market as well.

Market Segmentation The global cell viability assays market is segmented as below: Product: o Consumables

o Instruments

Geographic Segmentation: o North America

o APAC

o Europe

o South America

o MEA

Key Trends for global cell viability assays market growth This study identifies growing focus on stem cell research as the prime reasons driving the global cell viability assays market growth during the next few years.

Prominent vendors in global cell viability assays market We provide a detailed analysis of around 25 vendors operating in the global cell viability assays market, including some of the vendors such as Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Biotium Inc., Danaher Corp., General Electric Co., Merck KGaA, PerkinElmer Inc., Promega Corp. and Thermo Fisher Scientific Inc. . The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.Read the full report: https://www.reportlinker.com/p05868124/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original here:
The Global Cell Viability Assays MARKET is expected to grow by USD 1.40 bn during 2020-2024, progressing at a CAGR of 8% during the forecast period -...

BioIVT Now Provides Same-day Delivery of Fresh Leukopaks and Immune Cell Products in the UK and Over – PharmiWeb.com

WESTBURY, N.Y., March 3, 2020 /PRNewswire/ --BioIVT, a leading provider of research models and services for drug and diagnostic development, announced that it is now providing same-day delivery of fresh blood, LEUKOMAX leukopaks and buffy coats from normal and disease-state donors to cell and gene therapy researchers in the UK. BioIVT is also shipping these products overnight to certain EU locations.

This service is being offered through BioIVT's CTLS donor center in London, which sees more than 2,500 donors per year. Since BioIVT acquired CTLS in 2018, it has expanded CTLS' capabilities by introducing Spectra Optia apheresis systems, which allow it to collect leukopaks on site. BioIVT is now a premier provider of fresh leukopaks to the EU community.

"BioIVT is continuing to grow its business strategically to meet the exact needs of our clients. We currently have six donor centers located in California, Tennessee, Pennsylvania, and London. The placement of our sites allows us to provide cell and gene therapy researchers across the US, UK and Europe with viable solutions precisely when they need them," said BioIVT CEO Jeff Gatz.

"The UK is a hub for cell therapy, gene therapy and pharmaceutical companies who all require access to fresh blood and blood-derived immune cells for their research," said BioIVT General Manager of EU Operations Kelly Sapsford. "As speed is of the essence for many of these clients, we have improved the efficiency with which we produce our high-quality blood products to allow same-day delivery."

Leukopaks contain concentrated white blood cells and are used to help identify promising new drug candidates, assess toxicity levels, and conduct stem cell and gene therapy research. They are useful for researchers who need to obtain large numbers of leukocytes from a single donor.

BioIVT can also provide isolated peripheral blood mononuclear cells (PBMCs) from its leukopaks to meet specific donor and specimen parameters. Both leukopaks and isolated PBMCs can be provided from repeat donors and those that have been human leukocyte antigen (HLA), FC receptor or cytomegalovirus typed. HLA typing is used to match patients and donors for bone marrow or cord blood transplants. FC receptors plays an important role in antibody-dependent immune responses.

Donors can be recruited based on specific criteria, such as body mass index, smoking status, age, gender, ethnicity and in some cases medications taken. All BioIVT donors are consented under institutional review board (IRB-) approved protocols and its staff follows European Medicines Agency (EMA) standards and American Association of Blood Banks (AABB) guidelines.

Further information about BioIVT's new UK-based product lines is available at https://hubs.ly/H0ngR8G0.

About BioIVTBioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit http://www.bioivt.com or follow the company on Twitter @BioIVT.

BioIVT Contact: Courtney Noah, SVP, Marketing & Client Services, 516-483-1196Media Contact: Lisa Osborne, Rana Healthcare Solutions, 206-992-5245, lisa@ranahealth.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/bioivt-now-provides-same-day-delivery-of-fresh-leukopaks-and-immune-cell-products-in-the-uk-and-overnight-to-eu-locations-301014818.html

SOURCE BioIVT

Read the original here:
BioIVT Now Provides Same-day Delivery of Fresh Leukopaks and Immune Cell Products in the UK and Over - PharmiWeb.com

$6.36 Billion Flow Cytometry Market by Product & Solution, Technology, Application, End-user and Region – Forecast to 2027 -…

DUBLIN--(BUSINESS WIRE)--The "Flow Cytometry Market by Product and Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The global flow cytometry market is expected to grow at a CAGR of 8.2% from 2019 to 2027 to reach $6.36 billion by 2027.

The growth in the overall flow cytometry market is mainly attributed to rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. In addition, evolving pipeline for stem cell research and adoption of recombinant DNA technology for antibody production will further provide significant opportunities for the various stakeholders in this market.

The overall flow cytometry market is mainly segmented by product and solution (instruments, software, accessories, services), technology (cell-based flow cytometry, bead-based flow cytometry), application (research, clinical, and industrial), end-user (research and academic institutes, diagnostic laboratories, pharmaceutical & biotechnology companies), and geography.

On the basis of technology, bead-based technology segment is expected to grow at the highest CAGR during the forecast period. Procedural advantages offered by this technology over other cell-based technologies (such as ELISA and western blot), including its capacity to detect multiple analytes, high reproducibility, stability, and speed are expected to propel its growth.

On the basis of product and solution, the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019. Frequent utilization of application-specific reagents and assays by the end users is supporting the growth of this segment.

On the basis of application area, drug discovery segment held the largest share of the overall flow cytometry market in 2019. A wide variety of flow cytometry methods with the implementation of multi-parameter intracellular flow cytometric analysis have been employed at different stages of drug discovery and development. The growing demand for such advanced technologies used during drug discovery processes to simplify complicated cell analysis procedures is expected to drive the growth of this segment.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of this market in 2019. Increasing chronic cases leading to the development of new drugs and rise in R&D expenditure by companies is contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the flow cytometry market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMerieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Market Dynamics

Drivers

Restraint

Opportunities

Challenges

Scope of the Report

Global Flow Cytometry Market, by Technology

Global Flow Cytometry Market, by Product & Services

Global Flow Cytometry Market, by Application

Global Flow Cytometry Market, by End User

Global Flow Cytometry Market, by Geography

Company Profiles

(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)

For more information about this report visit https://www.researchandmarkets.com/r/16q5f

Continued here:
$6.36 Billion Flow Cytometry Market by Product & Solution, Technology, Application, End-user and Region - Forecast to 2027 -...

Human Embryonic Stem Cell (hESC) Market 2020 By Top Key Players/Manufacturers, Type and Application, Regions, Industry Analysis, Growth, Size, Trends,…

Global Human Embryonic Stem Cell (hESC) Market Overview:

The global Human Embryonic Stem Cell (hESC) Market is comprehensively analyzed in the report with a huge focus on industry dynamics, competitive landscape, regional and country-level analysis, segmental analysis, and major growth strategies. The market size in terms of both revenue and volume has been included in the report for the period 2015-2026. Moreover, the report provides qualitative business environment information which has been formulated by using tools such as PESTEL analysis, Porters Five Forces, and SWOT analysis.

The global Human Embryonic Stem Cell (hESC) Market accounted for a market size of $XXX million in 2019 and is anticipated to register a CAGR of XX% over the forecast period.

Download Free Sample Report Copy of Human Embryonic Stem Cell (hESC) Market Now @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/request-sample

Market Segmentation:

The global Human Embryonic Stem Cell (hESC) Market is segmented on the basis of segment 1, segment 2, segment 3, and segment 4. The report includes detailed information on all market segments and sub-segments and the factors impacting the market growth. In addition, the report consists of the market size of all the segments and sub-segments for historical and the forecast period along with compound annual growth rate (CAGR).

The global Human Embryonic Stem Cell (hESC) Market has been segmented into:

By Type:

Totipotent Stem CellPluripotent Stem CellUnipotent Stem Cell

By Application:

ResearchClinical TrialsOthers

Request Table of Content and Figures @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/toc

Regional Analysis

On regional and country-level, the market has been segmented as follows:

The report includes an in-depth assessment of all market segments in each region and country in the study scope. In addition, the study includes the market size for all regions and countries from the year 2015 to 2026. Macro-economic and micro-economic factors influencing the market growth in each region has been studied comprehensively in the report. Further, the report consist of recent market developments in each country.

Competitive Landscape:

The study involves company profiles of various key companies operating in the global Human Embryonic Stem Cell (hESC) Market. The financial outlooks of these companies, their research and development statuses, product offering, and their development strategies for the coming years are provided in the report. In addition, the report consists of a comprehensive list of the strategic initiatives undertaken by prominent companies in recent years to obtain a competitive edge in the market.

Prominent Companies in the global Human Embryonic Stem Cell (hESC) Market:

Astellas Institute of Regenerative Medicine (US)Asterias Biotherapeutics, Inc. (US)BD Biosciences (US)Cell Cure Neurosciences Ltd. (Israel)Cellular Dynamics International (US)GE Healthcare (UK)MilliporeSigma (US)PerkinElmer, Inc. (US)Reliance Life Sciences Ltd. (India)Research & Diagnostics Systems, Inc. (US)SABiosciences Corp. (US)STEMCELL Technologies, Inc. (Canada)Stemina Biomarker Discovery, Inc. (US)Takara Bio, Inc. (Japan)TATAA Biocenter AB (Sweden)Thermo Fisher Scientific, Inc. (US)UK Stem Cell Bank (UK)ViaCyte, Inc. (US)Vitrolife AB (Sweden)

You Can Directly Buy This Report from Here (Get Instant Discount $1000) @ http://researchindustry.us/checkout?report=788874&type=single

Research Methodology:

The research methodology adopted for formulating the global Human Embryonic Stem Cell (hESC) Market report is based on detailed primary and secondary research. For primary research, interviews were conducted with key opinion leaders such as market stakeholders, investors, brand managers, vice presidents, sales managers, and marketing managers. Based on data obtained from primary respondents, the changing scenario of the global Human Embryonic Stem Cell (hESC) Market was emphasized. Further, for secondary research, various public and paid databases were utilized along with annual report publications, white papers, and key players press releases to obtain the required data for analysis. Moreover, a mixture of bottom-up and top-down approaches were utilized for market engineering process.

Reasons to Purchase Global Human Embryonic Stem Cell (hESC) Report

Request Customization or Discount of This Report @ http://researchindustry.us/report/human-embryonic-stem-cell-hesc-market-rie/788874/request-customization

Pointers Covered in TOC:

Chapter 1: This chapter includes executive summary, market definition and market scope.

Chapter 2:This chapter includes in-depth research methodology, information procurement, data analysis, assumptions & exclusions, and secondary data resources.

Chapter 3: This chapter consists of market trends, drivers, restraints, opportunities, business environment analysis tools, and market share analysis.

Chapter 4, 5, 6:These chapters consist of information of all market segments including market size and forecast (2019-2026).

Chapter 7: This chapter includes regional and country level analysis of global Human Embryonic Stem Cell (hESC) Market.

Chapter 8: This chapter includes company profiles of key market players

Chapter 9: List of Tables

Chapter 10: List of Figures

Research Industry US is a market research and consultative company that provides market research reports and business insights to large and small & medium enterprises. The company supports its clients to conceive business policies and accomplish sustainable growth in their particular market domain. We meet clients objectives, commitment and dedication on high standard and targeting possible prospects for market research reports. We value how imperative surveying statistical information is for your business or association. As a result, we are linked with the top publishers & research firms all dedicated in specific domains, ensuring you will receive the most consistent and up to date research data available.

Get In Touch!Research Industry USNavale ICON IT Park,Office No. 407, Mumbai Bangalore Highway, Narhe, PuneUSA:+1-213-275-4706IND+91-844-601-6060Email:[emailprotected]

Link:
Human Embryonic Stem Cell (hESC) Market 2020 By Top Key Players/Manufacturers, Type and Application, Regions, Industry Analysis, Growth, Size, Trends,...

‘Research Week’ Celebrates UC Merced Innovation | Newsroom – UC Merced University News

By Michelle Morgante, UC Merced

UC Merced celebrates Research Week from March 2-6 to highlight the ground-breaking work taking place on campus.

UC Merced celebrates Research Week from March 2-6 to highlight the ground-breaking work taking place at the University of Californias newest campus.

The annual week of events, sponsored by the Office of Research and Economic Development , is an opportunity for all to see the innovative projects emerging from UC Merced.

Research Week is a fantastic opportunity to have an up-close experience with the newest research from across disciplines emerging from our campus work that will shape our future, said Vice Chancellor for Research and Economic Development Sam Traina. We encourage everyone to come out and learn about the great things happening at UC Merced.

The community is invited to participate in events, talks and tours throughout the week. Several events are specifically organized to engage the public:

Addressing Climate Change, presented by the Sierra Nevada Research Institute

Monday, March 2, 10 a.m.-12:15 p.m. in the California Room

Researchers will hold a series of presentations on efforts to address climate change. At 11:45 a.m., the 25-minute film Beyond the Brink - Californias Watershed will be presented. The program includes lunch and a poster session.

Tours of the Merced Vernal Pools and Grassland Reserve are offered as part of Research Week.

Core Facilities Tours

Tuesday, March 3, 1-3 p.m. starting from the Science and Engineering Building 1 Breezeway

The public is invited to participate in tours of the campuss core facilities: the Merced Vernal Pools and Grassland Reserve; the Stable Isotope Laboratory; the Stem Cell Instrumentation Foundry; the Department of Animal Research Services; the Environmental Analytical Laboratory; the Imaging and Microscopy Facility; the Nuclear Magnetic Resonance Lab; the MERCED (Multi-Environmental Research Computer for Exploration and Discovery) Cluster, and the WAVE (Wide Area Visualization Environment) Lab.

Tours of all facilities except the reserve begin at 1 p.m. and depart every 30 minutes. Tours of the Merced Vernal Pools and Grassland Reserve depart promptly at 1 p.m. and 2:30 p.m. and last 90 minutes. Participation is on a first-come, first-served basis.

It is exciting to be able to open up these important facilities to the local community, Traina said. These spaces, and the instruments and resources they contain, are part of the reason why UC Merced is a top-tier research institution.

Poster Showcase/Merced County Office of Education STEM Fair

Wednesday, March 4, 9:30 a.m.-1 p.m. in the Joseph Edward Gallo Recreation and Wellness Center Gym

The annual exhibit of posters by UC Merced undergraduate and graduate students in all disciplines will be displayed and serve as inspiration to Merced County 5th- through 8th-grade students who have advanced from STEM fairs at the school district level. The STEM Fair is the qualifying event for the California Science and Engineering Fair, and the younger students will present their projects, go on a tour of UC Merced, have lunch with UC Merced researchers and administrators and participate in hands-on science displays by campus scientists. The campus community is encouraged to come see UC Merced students research posters and meet some of Merced Countys brightest young scientists in the STEM Fair.

The Merced County Office of Education STEM Fair is held in conjunction with Research Week.

GradSTORY, presented by RadioBio

Thursday March 5, 10 a.m.-2 p.m.; The Pavilion dining commons

Graduate students will discuss their research and their journeys to graduate school through brief interviews with the proudcers of the RadioBio podcast.

ReCCES Community Reception

Thursday, March 5, 5 p.m.-6:30 p.m., Merced Civic Center-Sam Pipes Room

The Resource Center for Community Engaged Scholarship and the Undergraduate Research Opportunities Center welcome the community to a reception where people can hear from professors conducting community-engaged research and meet undergraduate and graduate students to learn about their involvement in the community. Refreshments provided.

CITRIS Ag-Food Tech Spring Seminar

Friday, March 6, Noon., Classroom and Office Building 2, room 140

Melba Crawford, associate dean of Engineering for Research at Purdue University, is the featured speaker of the Ag-Food Tech Spring Seminar by the Center for Information Technology Research in the Interest of Society.

More information about Research Week events can be found online.

See the rest here:
'Research Week' Celebrates UC Merced Innovation | Newsroom - UC Merced University News

The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% – GlobeNewswire

New York, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single-cell Analysis Market by Cell Type, Product, Technique, Application, End User - Global Forecasts to 2025" - https://www.reportlinker.com/p04579530/?utm_source=GNW However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The academic & research laboratories segment accounted for the largest market share in 2018On the basis of end user, the single-cell analysis market is segmented into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and cell banks and IVF centers.The academic and research laboratories segment accounted for the largest market share in 2018.

Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Flow cytometry is the largest technique segment of the single-cell analysis marketBased on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques.The flow cytometry segment accounted for the largest market share in 2018.

The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles.

North America will continue to dominate the single-cell analysis market in 2025The single-cell analysis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.In 2018, North America accounted for the largest share of the single-cell analysis market.

The large share of North America can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

The breakup of primary participants is as mentioned below: By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25% By Designation - C-level: 35%, Director-level: 25%, and Others: 40% By Region - North America: 40%, Europe: 20%, Asia Pacific: 25%, Latin America: 10%, and the Middle East & Africa: 5%

Prominent players in the single-cell analysis market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Research Coverage:The report analyzes the single-cell analysis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, cell type, technique, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights into: Market Penetration: Comprehensive information on the product portfolios of the top players in the single-cell analysis market. The report analyzes this market by product, application, cell type, technique, end user, and region Market Development: Comprehensive information on the lucrative emerging markets by product, application, cell type, technique, end user, and region Market Diversification: Exhaustive information about products, growing geographies, recent developments, and investments in the single-cell analysis market Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the single-cell analysis marketRead the full report: https://www.reportlinker.com/p04579530/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Here is the original post:
The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% - GlobeNewswire

AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells – Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a new paper co-authored by two AgeX scientists that could lead to new insights into the fundamental mechanisms of aging and why super-centenarians not only live the longest, but also experience extraordinary healthspans; an extension of the healthy years of life that compresses morbidity to a very short period near the end of life. The paper, Induced pluripotency and spontaneous reversal of cellular aging in supercentenarian donor cells, is published online in the peer-reviewed scientific journal Biochemical and Biophysical Research Communications from Elsevier. The senior author is Dana Larocca, PhD, VP of Discovery Research at AgeX, and the first author is Jieun Lee, PhD, Scientist at AgeX.

Clearly, we can learn a lot about aging and longevity from the longest of the long-lived, the supercentenarians, and we hope that this paper accelerates such research, commented Dr. Larocca. Now that we have converted the cells of one of the longest-lived people in history, a deceased 114-year-old American woman, to a young pluripotent state, researchers can do so with cells from other supercentenarians. The goal is to understand specifically how these extreme agers manage to avoid the major chronic illnesses of aging better than any other age group including centenarians. We can essentially put their cells in a time machine and revert them to an earlier state, then study their biology to help unlock the mysteries of super-longevity. Scientists have long wondered, and now we know that we can indeed reset the developmental state and cellular age in the oldest of the old.

By way of comparison, the paper also describes undertaking a similar process with cells from two other donors: an eight-year-old with a rapid-aging syndrome commonly known as Progeria, and a 43-year-old, healthy disease-free control (HDC) subject. The paper notes that the supercentenarians cells reverted to induced pluripotent stem (iPS) cells at the same rate as the HDC subject and the Progeria patient. However, there may be some negative impact of extreme age on telomere resetting as this did not occur as frequently in the supercentenarian as in the other two donors.

The donated cells were from the longevity collection, a cell bank established by the NIHs National Institute on Aging.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

More here:
AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells - Business Wire

Woman of Wellness to hear from San Diego Blood Bank representative – Fallbrook / Bonsall Villlage News

FALLBROOK Woman of Wellness meets Thursday, March 5, at 6 p.m. for San Diego Blood Bank Saving Lives Today, Improving Life Tomorrow at Fallbrook Library, 124 S. Mission Road.

Fallbrook Regional Health Districts Woman of Wellness Program is looking forward to a presentation by Rob Tressler, Ph.D., vice president of laboratories for the San Diego Blood Bank. He oversees the public cord blood bank and cell therapy research program. His scientific focus is in stem cell biology, oncology and anti-aging research. Tressler will discuss how the blood bank is saving lives with traditional blood donation, as well as improving life tomorrow with the stem cell therapy research and other exciting programs.

In addition, FRHD will sponsor a blood drive March 31, at the administrative office, 138 S. Brandon Road, Fallbrook. Watch for details and mark the calendar now as this opportunity to donate blood.

Fallbrook Regional Health District invites men and women to Woman of Wellness each first Thursday of the month, except for this event on the second Thursday. A social time begins at 6 p.m., followed by the presentation at 6:30 p.m. This free event includes refreshments. Donations of non-perishable food items are collected for the Fallbrook Food Pantry.

For more information, call (760) 731-9187.

Submitted by Fallbrook Regional Health District.

See the rest here:
Woman of Wellness to hear from San Diego Blood Bank representative - Fallbrook / Bonsall Villlage News